PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30363935-3	2018	However, the recent development of continuous glucose monitoring (CGM) and new biomedical sensors/gadgets, based on automatic continuous monitoring, offers a new perspective on DM1 management, since these innovative devices allow the collection of 24-hour biomedical data in addition to blood glucose levels.	Glucose	46-53	immunoglobulin heavy diversity 1-7	Homo sapiens	177-180	
32224027-2	2020	Insulin therapy for type 1 DM (DM1) can achieve overall blood glucose control, but glycemic variations can occur during injection intervals, which may contribute to some complications.	Glucose	62-69	immunoglobulin heavy diversity 1-7	Homo sapiens	31-34	
11774802-5	2001	Of the persons with DM1, 24% of them had a blood glucose level of < 4.4 mmol/L; this was true for 15% of those with DM2.	Glucose	49-56	immunoglobulin heavy diversity 1-7	Homo sapiens	20-23	
11774802-6	2001	The proportion of persons with a blood glucose level of > 7.7 mmol/L was 41% among those with DM1 and 57% among those with DM2.	Glucose	39-46	immunoglobulin heavy diversity 1-7	Homo sapiens	97-100	
30357807-2	2019	We hypothesised that similar treatment of DM1 and DM2 patients leads to differences in their perioperative glucose control.	Glucose	107-114	immunoglobulin heavy diversity 1-7	Homo sapiens	42-45	
30357807-9	2019	Compared to those with DM2, patients with DM1 were younger, had a lower BMI, a higher glucose concentration before surgery, and a higher perioperative peak glucose concentration (11.0 [8.2-14.7] vs 9.4 [7.7-11.7], P < 0.001).	Glucose	86-93	immunoglobulin heavy diversity 1-7	Homo sapiens	42-45	
30357807-9	2019	Compared to those with DM2, patients with DM1 were younger, had a lower BMI, a higher glucose concentration before surgery, and a higher perioperative peak glucose concentration (11.0 [8.2-14.7] vs 9.4 [7.7-11.7], P < 0.001).	Glucose	156-163	immunoglobulin heavy diversity 1-7	Homo sapiens	42-45	
30363935-3	2018	However, the recent development of continuous glucose monitoring (CGM) and new biomedical sensors/gadgets, based on automatic continuous monitoring, offers a new perspective on DM1 management, since these innovative devices allow the collection of 24-hour biomedical data in addition to blood glucose levels.	Glucose	293-300	immunoglobulin heavy diversity 1-7	Homo sapiens	177-180	
24392467-2	2014	Diabetes Mellitus type I (DM1) and II (DM2) share the common characteristic of high blood glucose concentration and the health complications resulting from uncontrolled hyperglycemia such as hyperlipidemia, cardiovascular problems, stroke, ketoacidosis, kidney failure and blindness but have different etiology.	Glucose	90-97	immunoglobulin heavy diversity 1-7	Homo sapiens	26-29	
15131773-9	2004	The metabolic clearance rates of glucose (MCR) were lower in DM1 compared with C in period 1 (12.54 +/- 3.38 v 17.41 +/- 6.18 mL.	Glucose	33-40	immunoglobulin heavy diversity 1-7	Homo sapiens	61-64	
20219586-3	2010	In the DM1 group, metabolic control data were observed (glycosylated hemoglobin (GHb) and capillary glucose), whereby GHb < or =8.0% was considered to indicate good metabolic control (DM1-A) and >8.0% poor metabolic control (DM1-B).	Glucose	100-107	immunoglobulin heavy diversity 1-7	Homo sapiens	7-10	
23371411-3	2013	BMI, level of fasting plasma glucose (FPG), and concentrations of total cholesterol (TCH), LDL cholesterol (LDL-C), and IL-6 were higher in DM1 patients compared to the control group.	Glucose	29-36	immunoglobulin heavy diversity 1-7	Homo sapiens	140-143	
15859552-7	2005	However multifactor analysis indicates that the only significant risk factors for DM 1 are early onset of diabetes during pregnancy and high glucose levels 2 hours after OGTT during pregnancy (p < 0.05).	Glucose	141-148	immunoglobulin heavy diversity 1-7	Homo sapiens	82-86